Most of these studies align with the well-established drug-protective effects of NF-kB signaling, yet it should be noted that both WNT and STAT3 signaling pathways are also implicated in cancer drug resistance suggesting a potentially multi-faceted role for BCL3 in driving drug resistance in different tumour contexts [118–120]. This evidence concerns the gene NFKB1 and cancer.